Cargando…

HER2 Status in Gastric and Gastroesophageal Junction Cancer Assessed by Local and Central Laboratories: Chinese Results of the HER-EAGLE Study

Trastuzumab has been approved for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric and gastroesophageal junction cancers (GC and GJC) in combination with chemotherapy. The aim of this HER2 early/advanced gastric epidemiology (HER-EAGLE) study was to evaluate the frequency of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Dan, Lu, Ning, Fan, Qinhe, Sheng, Weiqi, Bu, Hong, Jin, Xiaolong, Li, Guimei, Liu, Yanhui, Li, Xianghong, Sun, Wenyong, Zhang, Huizhong, Li, Xiaobing, Zhou, Zongguang, Yan, Min, Wang, Xuan, Sha, Weihong, Ji, Jiafu, Cheng, Xiangdong, Zhou, Zhiwei, Xu, Jianming, Du, Xiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828190/ https://www.ncbi.nlm.nih.gov/pubmed/24244671 http://dx.doi.org/10.1371/journal.pone.0080290

Ejemplares similares

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
por: Zhao, Dan, et al.
Publicado: (2019)

HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population
por: Shan, Ling, et al.
Publicado: (2013)

Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma
por: Sigrand, Julie, et al.
Publicado: (2016)

Gene Signal Distribution and HER2 Amplification in Gastroesophageal Cancer
por: Jørgensen, Jan Trøst, et al.
Publicado: (2017)

Her-2 Expression in Gastroesophageal Intestinal Metaplasia, Dysplasia, and Adenocarcinoma
por: Almhanna, Khaldoun, et al.
Publicado: (2016)

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
por: Van Cutsem, Eric, et al.
Publicado: (2014)

Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma
por: Catenacci, D.V.T., et al.
Publicado: (2021)

Association between HSP90 and Her2 in Gastric and Gastroesophageal Carcinomas
por: Berezowska, Sabina, et al.
Publicado: (2013)

Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers
por: Chuang, Jeremy, et al.
Publicado: (2022)

Digital Image Analysis of HER2 Immunostained Gastric and Gastroesophageal Junction Adenocarcinomas
por: Nielsen, Sofie L., et al.
Publicado: (2017)

HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
por: Li, Weiling, et al.
Publicado: (2022)

HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction
por: Ecker, Brett L., et al.
Publicado: (2016)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

HER2-Positive Gastroesophageal Cancers Are Associated with a Higher Risk of Brain Metastasis
por: Tincknell, Gary, et al.
Publicado: (2022)

The potential of mRNA expression evaluation in predicting HER2 positivity in gastroesophageal cancer
por: de Oliveira, I.M., et al.
Publicado: (2022)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population
por: Lago, Nieves Martínez, et al.
Publicado: (2020)

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer
por: Esen, Selin Aktürk, et al.
Publicado: (2022)

Synergistic Effects of Metformin and Trastuzumab on HER2 Positive Gastroesophageal Adenocarcinoma Cells In Vitro and In Vivo
por: Kim, Jin-Soo, et al.
Publicado: (2023)

Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
por: Peng, Zhi, et al.
Publicado: (2021)

Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial
por: Liu, Tianshu, et al.
Publicado: (2019)

A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo
por: Shu, Mengjun, et al.
Publicado: (2020)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas
por: Wang, Xin-Yu, et al.
Publicado: (2019)

PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study
por: Beer, Andrea, et al.
Publicado: (2020)

PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma
por: Yokoyama, Daiju, et al.
Publicado: (2021)

Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era
por: Radford, Maluki, et al.
Publicado: (2023)

FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis
por: Chen, Shinan, et al.
Publicado: (2018)

The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition
por: Shi, Jiaolong, et al.
Publicado: (2018)

HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma
por: Liu, Zimin, et al.
Publicado: (2021)

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
por: Yang, Liu, et al.
Publicado: (2022)

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
por: Cai, Mengyuan, et al.
Publicado: (2023)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma
por: HUANG, JUN-XING, et al.
Publicado: (2013)

Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer
por: Kirschbrown, Whitney P., et al.
Publicado: (2019)

Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
por: Dijksterhuis, Willemieke P. M., et al.
Publicado: (2020)

Clinical outcomes of patients with HER2-mutant advanced lung cancer: chemotherapies versus HER2-directed therapies
por: Zhou, Jiebai, et al.
Publicado: (2020)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
por: Ma, Jing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sr7qql7oqs6pf2ftr973p1qqse